Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN116865 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-IL-6 antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant Human IL-6 produced in E.coli.
- Description
- Serum
- Reactivity
- Human
- Host
- Rabbit
- Antigen sequence
Protein Sequence: Human Interleukin
6, 212 aa, predicted MW 23.7 kDa 1
mnsfstsafg pvafslglll vlpaafpapv p
pgedskdva aphrqpltss eridkqiryi 61
ldgisalrke tcnksnmces skealaennl nl
pkmaekdg cfqsgfneet clvkiitgll 121
efevyleylq nrfesseeqa ravqmstkvl iq
flqkkakn ldaittpdpt tnaslltklq 181
aqnqwlqdmt thlilrsfke flqsslralr qm- Vial size
- 1 mL
- Concentration
- 80 mg/mL (by refractometry)
- Storage
- Store the antibody undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer.
- Handling
- Avoid repeated freezing and thawing. This product is photosensitive and should be protected from light.
Submitted references Expression of TGF-beta isoforms by Thy-1+ and Thy-1- pulmonary fibroblast subsets: evidence for TGF-beta as a regulator of IL-1-dependent stimulation of IL-6.
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity.
Silvera MR, Sempowski GD, Phipps RP
Lymphokine and cytokine research 1994 Oct;13(5):277-85
Lymphokine and cytokine research 1994 Oct;13(5):277-85
Enhancement of interleukin 6 cytostatic effect on human breast carcinoma cells by soluble IL-6 receptor from urine and reversion by monoclonal antibody.
Novick D, Shulman LM, Chen L, Revel M
Cytokine 1992 Jan;4(1):6-11
Cytokine 1992 Jan;4(1):6-11
Monoclonal antibodies for affinity purification of IL-6/IFN- beta 2 and for neutralization of HGF activity.
Novick D, Eshhar Z, Revel M, Mory Y
Hybridoma 1989 Oct;8(5):561-7
Hybridoma 1989 Oct;8(5):561-7
No comments: Submit comment
No validations: Submit validation data